| 001 | 275770 | ||
| 005 | 20240918111959.0 | ||
| 024 | 7 | _ | |a 10.1007/s11033-023-08477-3 |2 doi |
| 024 | 7 | _ | |a pmid:37127809 |2 pmid |
| 024 | 7 | _ | |a 0301-4851 |2 ISSN |
| 024 | 7 | _ | |a 1573-4978 |2 ISSN |
| 024 | 7 | _ | |a altmetric:147160188 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2023-00869 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 570 |
| 100 | 1 | _ | |a Pervaiz, Asim |0 P:(DE-He78)17064a887f14c1cee3ae16af3cf73314 |b 0 |e First author |
| 245 | _ | _ | |a Anticancer genes (NOXA, PAR-4, TRAIL) are de-regulated in breast cancer patients and can be targeted by using a ribosomal inactivating plant protein (riproximin). |
| 260 | _ | _ | |a Dordrecht [u.a.] |c 2023 |b Springer Science + Business Media B.V |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1726651171_8429 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2023 Jun;50(6):5209-5221 / #EA:G401#LA:G401# |
| 520 | _ | _ | |a Anticancer genes are an endogenous defense against transformed cells as they impose antineoplastic effects upon ectopic expression. Profiling the expression of these genes is fundamental for exploring their prognostic and therapeutic relevance in cancers. Natural compounds can upregulate anticancer genes in malignant cells and thus be useful for therapeutic purposes. In this study, we identified the expression levels of anticancer genes in breast cancer clinical isolates. In addition, the purified and sequenced plant protein (riproximin) was evaluated for its potential to induce anticancer genes in two breast cancer cell lines.Expression profiles of three anticancer genes (NOXA, PAR-4, TRAIL) were identified by immunohistochemistry in 45 breast cancer clinical isolates. Breast cancer cells were exposed to riproximin and expression of the anticancer genes was determined by microarray, real-time PCR and western blot methodologies. Lastly, a bioinformatic approach was adopted to highlight the molecular/functional significance of the anticancer genes.NOXA expression was evenly de-regulated among the clinical isolates, while PAR-4 was significantly down-regulated in majority of the breast cancer tissues. In contrast, TRAIL expression was increased in most of the clinical samples. Expression levels of the anticancer genes followed a distinct trend in accordance with the disease severity. Riproximin showed a substantial potential of inducing expression of the anticancer genes in breast cancer cells at transcriptomic and protein levels. The bioinformatic approach revealed involvement of anticancer genes in multiple cellular functions and signaling cascades.Anticancer genes were de-regulated and showed discrete expression patterns in breast cancer patient samples. Riproximin effectively induced the expression of selected anticancer genes in breast cancer cells. |
| 536 | _ | _ | |a 311 - Zellbiologie und Tumorbiologie (POF4-311) |0 G:(DE-HGF)POF4-311 |c POF4-311 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Anticancer genes |2 Other |
| 650 | _ | 7 | |a Breast cancer |2 Other |
| 650 | _ | 7 | |a Plant protein |2 Other |
| 650 | _ | 7 | |a Riproximin |2 Other |
| 700 | 1 | _ | |a Naseem, Nadia |b 1 |
| 700 | 1 | _ | |a Saleem, Talha |b 2 |
| 700 | 1 | _ | |a Raza, Syed Mohsin |b 3 |
| 700 | 1 | _ | |a Shaukat, Iqra |b 4 |
| 700 | 1 | _ | |a Kanwal, Kinzah |b 5 |
| 700 | 1 | _ | |a Sajjad, Osheen |b 6 |
| 700 | 1 | _ | |a Iqbal, Sana |b 7 |
| 700 | 1 | _ | |a Shams, Faiza |b 8 |
| 700 | 1 | _ | |a Ijaz, Bushra |b 9 |
| 700 | 1 | _ | |a Berger, Martin |0 P:(DE-He78)7e60033e3eaaebb9ba30c905ade4a676 |b 10 |e Last author |
| 773 | _ | _ | |a 10.1007/s11033-023-08477-3 |0 PERI:(DE-600)1478217-0 |n 6 |p 5209-5221 |t Molecular biology reports |v 50 |y 2023 |x 0301-4851 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:275770 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)17064a887f14c1cee3ae16af3cf73314 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)7e60033e3eaaebb9ba30c905ade4a676 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-311 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Zellbiologie und Tumorbiologie |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2022-11-09 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2022-11-09 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2022-11-09 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-09 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-21 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MOL BIOL REP : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-21 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2023-10-21 |
| 920 | 2 | _ | |0 I:(DE-He78)G401-20160331 |k G401 |l Molekulare Toxikologie und Chemotherapie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)G401-20160331 |k G401 |l Molekulare Toxikologie und Chemotherapie |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)G401-20160331 |k G401 |l Molekulare Toxikologie und Chemotherapie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)G401-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::